<SEC-DOCUMENT>0001628280-24-034743.txt : 20240805
<SEC-HEADER>0001628280-24-034743.hdr.sgml : 20240805
<ACCEPTANCE-DATETIME>20240805161624
ACCESSION NUMBER:		0001628280-24-034743
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240805
DATE AS OF CHANGE:		20240805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDIFAST INC
		CENTRAL INDEX KEY:			0000910329
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				133714405
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31573
		FILM NUMBER:		241174987

	BUSINESS ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117
		BUSINESS PHONE:		7327640619

	MAIL ADDRESS:	
		STREET 1:		11445 CRONHILL DRIVE
		CITY:			OWINGS MILLS
		STATE:			MD
		ZIP:			21117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHRITE INC
		DATE OF NAME CHANGE:	19951120

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XX
		DATE OF NAME CHANGE:	19950619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	00
		DATE OF NAME CHANGE:	19950619
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>med-20240805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:272a0a2e-e851-4d4b-9f7d-f044ebddd625,g:0fca923f-655c-4461-900c-20701eed3f36,d:0ae3397883d144c393fca3649d7c8ce3-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>med-20240805</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000910329</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="med-20240805.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000910329</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-05</xbrli:startDate><xbrli:endDate>2024-08-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0ae3397883d144c393fca3649d7c8ce3_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 5, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">MEDIFAST, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdiction of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-31573</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">13-3714405</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 International Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Baltimore</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">21202</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">410</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">581-8042</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">MED</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">New York Stock Exchange</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;General Instruction A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:96.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.578%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:324pt;text-align:right;text-indent:-324pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div id="i0ae3397883d144c393fca3649d7c8ce3_7"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 5, 2024, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the second quarter ended June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1993, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div id="i0ae3397883d144c393fca3649d7c8ce3_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Exhibits.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="medearningsrelease08052024.htm">Medifast Announces Second Quarter 2024 Financial Results</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i0ae3397883d144c393fca3649d7c8ce3_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MEDIFAST, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James P. Maloney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James P. Maloney</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 5, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>medearningsrelease08052024.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i72df10996a4d4ddeaa4b2da0243eac69_35"></div><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:125%">Medifast Announces Second Quarter 2024 Financial Results </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">August 5, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">BALTIMORE &#8211; (</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">BUSINESS WIRE</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">)--</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (NYSE&#58; MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, today reported results for the second quarter ended June 30, 2024.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Second Quarter 2024</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Revenue of $168.6 million, with revenue per active earning Coach of $4,972</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Independent active earning</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%"> OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coaches of 33,900</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Loss per diluted share of $0.75</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> (non-GAAP adjusted earnings per share (&#34;EPS&#34;) of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$0.92</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:12.53pt">Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;We are acting decisively to transform our business to position us for long-term growth, with a strong balance sheet free of debt, a clear focus on new customer acquisition, and a broader health and wellness offer to a significantly expanded target market,&#8221; said Dan Chard, Chairman &#38; CEO. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;Our holistic approach, encompassing nutrition, personalized coaching, a supportive community, and access to a clinician through our collaboration with telehealth provider, LifeMD, positions us uniquely to support those who are interested in weight loss medications as well as those who are transitioning off a medical regimen, or those who choose to pursue more traditional weight loss methods. Our mission today, much like it has been over the last 40 years, is to help our customers create lifestyle changes and establish healthy habits, and we are developing new plans and products to aid individuals in achieving healthier lifestyles. We believe we are more relevant than ever in today&#8217;s environment and are well positioned to shape the future of health and wellness, impacting millions of lives.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Second Quarter 2024 Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Second quarter 2024 revenue decreased 43.1% to $168.6 million from $296.2 million for the second quarter of 2023 primarily driven by a decrease in the number of active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coaches and lower Coach productivity. The total number of active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coaches decreased 36.2% to 33,900 compared to 53,100 for the second quarter of 2023. The average revenue per active earning </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coach decreased 10.9% to $4,972 compared to $5,578 for the second quarter last year, primarily driven by continued pressure on customer acquisition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Gross profit decreased 41.4% to $123.4 million from $210.7 million for the second quarter of 2023. The decrease in gross profi</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">t was primarily </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">due to lower revenue. Gross profit margin was 73.2% compared to 71.1% in the second quarter of 2023, primarily due to cost savings from the company&#8217;s Fuel for the Future initiatives and efficiencies in inventory management. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Non-GAAP adjusted gross profit, which </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">excludes expenses in connection with the company's restructuring of external manufacturing agreements,</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">decreased</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">40.2%</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$126.0 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">non-GAAP adjusted gross profit margin increased 370 basis points year-over-year to 74.8%.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Selling, general, and administrative expenses (&#8220;SG&#38;A&#8221;) decreased 23.7% to $131.3 million compared to $172.0 million for the second quarter of 2023. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">decrease</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> in SG&#38;A was primarily </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">due to lower </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coach compensation on fewer active earning Coaches and lower sales volumes, partially offset by the loss of leverage on fixed costs due to lower sales volumes and supply chain optimization costs. The Company also incurred market research and investment costs related to medically supported weight loss, costs to exit hotel commitments for the company&#8217;s annual </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA convention in future years reflecting a change in strategy, and costs for the company&#8217;s company-led customer acquisition initiatives. As a percentage of revenue, SG&#38;A increased 1,980</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> basis points </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">year-over-year to 77.9% of revenue, as compared to 58.1% for the second quarter of 2023. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">increase</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> in SG&#38;A as a percentage of revenue was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">primarily due to the loss of leverage on fixed costs due to lower sales volumes and sup</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">ply chain optimization costs. The Company also incurred market research and investment costs related to medically supported weight loss, costs to exit hotel commitments for the company&#8217;s annual </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA convention in future years reflecting a change in strategy, and costs for the company&#8217;s company-led customer acquisition initiatives. Non-GAAP adjusted </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">SG&#38;A, which excludes expenses related to the company&#8217;s supply chain optimization costs, costs to exit hotel commitments for the company&#8217;s annual </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA convention in future years, and costs for its collaboration with LifeMD, decreased</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> 33.8% to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$113.8 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">non-GAAP adjusted SG&#38;A as a percentage of revenue increased 940 basis points year-over-year to 67.5%. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company's loss from operations for the period was $7.9 million, a decrease of </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">120.3%, as compared to</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> income from operations of $38.7 million in the prior-year period. As a percentage of revenue, loss from operations was 4.7% for the second quarter of 2024 compared to income from operations as a percentage of revenue of 13.1% in the prior-year period. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Non-GAAP adjusted income from operations </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">decreased</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> 68.4% to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$12.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Non-GAAP adjusted income from operations as a percentage of revenue was 7.3%, a decrease of 580 basis points from the year-ago period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The effective tax rate was 23.4% for the second quarter of 2024 compared to 22.6% in the prior-year period. The increase in the effective tax rate for the three months ended June 30, 2024 was primarily driven by the net loss position in 2024 and the corresponding rate impact from research and development tax credits, partially offset by the rate impact from the limitation for executive compensation. The </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">non-GAAP effective tax rate was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">26.2%</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> as compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">22.6%</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> in the prior-year period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In the second quarter of 2024, the company's net loss was $8.2 million, or $0.75 per diluted share, based on approximately 10.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million shares </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">of common stock outstanding. In the second quarter of 2023, net income was $30.3 million, or $2.77 per diluted share, based on approximately 10.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million shares</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> of common stock outstanding.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> In the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">second</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> quarter </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">, non-GAAP adjusted net income was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$10.1</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> million, or </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">$0.92</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> per diluted share.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Capital Allocation and Balance Sheet</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company&#8217;s balance sheet remains strong with $163.5 million in cash, cash equivalents and investment securities and no interest-bearing debt as of June 30, 2024 compared to $150.0 million in cash, cash equivalents and investment securities and no debt at December 31, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Outlook</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The company expects third quarter 2024 revenue to be in the range of $125 million to $145 million and third quarter 2024 diluted loss per share in the range of $0.05 to $0.70. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company&#8217;s LifeMD common stock investment, which the company is unable to estimate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Conference Call Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The conference call is scheduled for today, Monday, August 5, 2023 at 4&#58;30 p.m. ET. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast&#8217;s website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">www.MedifastInc.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> or directly at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">https&#58;&#47;&#47;viavid.webcasts.com&#47;starthere.jsp&#63;ei&#61;1678505&#38;tp_key&#61;f8865fb1bd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> and will be archived online and available through November 5, 2024. In addition, listeners may dial (201) 389-0879 to join via telephone.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">A telephonic playback will be available from 8&#58;30 p.m. ET, August 5, 2024, through August 12, 2024. Participants can dial (412) 317-6671 and enter passcode 13747501 to hear the playback.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">About Medifast</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:700;line-height:125%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast (NYSE&#58; MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA&#174;, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA's holistic solution includes lifestyle plans with clinically proven health benefits, scientifically developed products, and a framework for habit creation &#8211; all reinforced by independent coach support for customers on their weight loss journeys. Through its collaboration with national virtual primary care provider LifeMD&#174; (Nasdaq&#58; LFMD) and its affiliated medical group, the holistic solution now includes access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature&#8482;. Visit the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA and Medifast websites for more information and follow &#64;Medifast on X and LinkedIn.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">MED-F</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Forward Looking Statements</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Please Note&#58; This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;expect&#8221; or other similar words or the negative of such terminology. Similarly, descriptions of Medifast&#8217;s objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Medifast's inability to maintain and grow the network of independent </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coaches&#59; Industry competition and new weight loss products, including weight loss medications, or services&#59; Medifast&#8217;s health or advertising related claims by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA customers&#59; Medifast's inability to continue to develop new products&#59; effectiveness of Medifast's advertising and marketing programs, including use of social media by </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">OPTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">VIA Coaches&#59; the departure of one or more key personnel&#59; Medifast's inability to protect against online security risks and cyberattacks&#59; risks associated with Medifast's direct-to-consumer business model&#59; disruptions in Medifast's supply chain&#59; product liability claims&#59; Medifast's planned growth into domestic markets including through its collaboration with LifeMD, Inc.&#59; adverse publicity associated with Medifast's products&#59; the impact of existing and future laws and regulations on Medifast&#8217;s business&#59; fluctuations of Medifast's common stock market price&#59; increases in litigation&#59; actions of activist investors&#59; the consequences of other geopolitical events, overall economic and market conditions and the resulting impact on consumer sentiment and spending patterns&#59; and Medifast's ability to prevent or detect a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Medifast, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Steven Zenker</font></div><div><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">InvestorRelations&#64;medifastinc.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">(443) 379-5256</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">MEDIFAST, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except per share amounts &#38; dividend data)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended June 30,</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Six months ended June 30,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$ 168,55</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">296,188&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">343,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">645,170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cost of sales</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">45,120</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">85,473</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,567</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">188,065</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Gross profit</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">123,438</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">210,715</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">250,730</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">457,105</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Selling, general, and administrative</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">131,314</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">172,009</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">250,666</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">364,887</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income (loss) from operations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(7,876)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">38,706</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">64</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">92,218</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other income (expense)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,296</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">462</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,519</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">281</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other expense</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(4,070)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(51)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,647)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(53)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2,774)</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">411</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">872</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">228</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Income (loss) from operations before income taxes</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(10,650)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">39,117</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">936</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">92,446</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Provision (benefit) for income taxes</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2,496)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,837</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">773</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22,198</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net income (loss)</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">(8,154)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$ 30,28</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">70,248</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings (loss) per share - basic</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.75)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings (loss) per share - diluted</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.75)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.77&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.01&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.43&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted average shares outstanding</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,937</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,888</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,923</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,876</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,937</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,917</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,967</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,923</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash dividends declared per share</font></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.65&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.30&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except par value)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 202</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 202</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current Assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108,016&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inventories</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">39,603</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54,591</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investments</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55,489</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55,601</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income taxes, prepaid</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,728</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">8,727</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,479</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,670</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">224,315</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">224,029</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment - net of accumulated depreciation</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">39,921</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">51,467</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,417</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,645</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11,770</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,650</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,108</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,117</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL ASSETS</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">293,531</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">309,908</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current Liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued expenses</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69,148&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">86,415&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current lease obligations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,031</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,885</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">75,179</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">92,300</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Lease obligations, net of current lease obligations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,069</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16,127</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">88,248</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">108,427</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders' Equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, par value $0.001 per share&#58; 20,000 shares authorized&#59;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,937 and 10,896 issued and outstanding</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">at June 30, 2024 and December 31, 2023, respectively</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,401</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26,573</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">248</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Retained earnings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">174,845</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">174,649</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders' equity</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">205,283</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">201,481</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">293,531</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</font></td><td style="border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">309,908</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</font></td><td style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In an effort to provide investors with additional information regarding Medifast&#8217;s results, we disclose various non-GAAP financial measures in the company&#8217;s quarterly earnings press release and other public disclosures. The following GAAP financial measures have been presented on an as adjusted basis&#58; gross profit, SG&#38;A expenses, income (loss) from operations, other income (expense), provision (benefit) for income taxes, net income (loss), effective tax rate, and diluted earnings (loss) per share. Each of these non-GAAP financial measures excludes the impact of certain amounts as further identified below that the company believes are not indicative of its core ongoing operational performance. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included below. These non-GAAP financial measures are not intended to replace GAAP financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">We use these non-GAAP financial measures internally to evaluate and manage the company's operations because we believe they provide useful supplemental information regarding the company's on-going economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results and as a means to emphasize the results of on-going operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The following tables reconcile the non-GAAP financial measures included in this release&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDIFAST, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED NON-GAAP (UNAUDITED)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(U.S. dollars in thousands, except per share amounts)</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:16.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three Months Ended June 30, 2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">GAAP </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Supply Chain Optimization and Restructuring of External Manufacturing Agreements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">OPTAVIA Convention Cancellation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Unrealized Loss on Investment in LifeMD Common Stock </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">LifeMD Prepaid Services Amortization </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Non-GAAP </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Gross profit</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">123,438&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,579&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">126,017&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Selling, general, and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">131,314</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(12,502)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(3,000)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,021)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">113,791</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Income (loss) from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(7,876)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">15,081</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,000</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,021</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">12,226</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,774)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">4,188</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,414</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Provision (benefit) for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(2,496)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,770</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">750</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,047</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">505</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,576</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(8,154)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">11,311</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2,250</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">3,141</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1,516</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">10,064</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted earnings (loss) per share</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(0.75)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">1.03</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.21</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.29</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.14</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">0.92</font></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures uses 10,962 thousand shares under the treasury stock method.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Three Months Ended June 30, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Supply Chain Optimization and Restructuring of External Manufacturing Agreements</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">OPTAVIA Convention Cancellation</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Unrealized Loss on Investment in LifeMD Common Stock</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">LifeMD Prepaid Services Amortization</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">Non-GAAP</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Gross profit</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">210,715&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">210,715&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Selling, general, and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">172,009</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">172,009</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Income from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">38,706</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">38,706</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Other income</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">411</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">411</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Provision for income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">8,837</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">8,837</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Net income</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">30,280</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">30,280</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">Diluted earnings per share </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:125%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2.77</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">2.77</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:125%">(1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>med-20240805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:272a0a2e-e851-4d4b-9f7d-f044ebddd625,g:0fca923f-655c-4461-900c-20701eed3f36-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:med="http://www.medifast1.com/20240805" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.medifast1.com/20240805">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20240805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="med-20240805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.medifast1.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>med-20240805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:272a0a2e-e851-4d4b-9f7d-f044ebddd625,g:0fca923f-655c-4461-900c-20701eed3f36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_946c5459-9a76-4362-b05c-01771ea3dc81_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_36a78e09-5bbf-49bd-9e68-f3f9ae037f36_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9fe5b5e2-21db-4796-b60a-93e90b51aa30_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_5e71cc32-4348-4252-8432-32974a7115e7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d4606093-83b4-45d6-9705-df7ce42308be_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_093da9ae-a771-4954-b35a-be71df19057f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d023d594-1d5a-4f43-8d31-15008518bc4c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d69fc8e8-2b63-44a5-9c68-27d4ddbecceb_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8c041910-2c66-4a71-b474-8d61f2e43e6c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_259eec13-972c-4b0a-b0b3-48eaec07569a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_e1b68986-84aa-4621-a876-6695a0a2c2dc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ca509070-1be9-410a-af34-bcfbb5e8856e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c84fd627-decd-478b-ba0d-94e0781d11a6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_964721a9-e50e-43e6-94cb-9c5fe324f976_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_598091f5-3462-4d77-ac5a-916c2a4f59ee_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fa8eadb7-4c31-4722-b3d0-abc06b68543b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cb66d856-fa1b-4ce9-875d-703bf775ff08_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_13e2734a-46e4-4e84-afb9-b0868ed90d52_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_828d6041-982f-45dd-a068-1679f41a8656_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_986bee12-75a8-47c7-9180-a93aec0cbcb2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ffe57893-6ce6-4c9a-b58a-bea9e18a750e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4fdc5fdf-6f46-4dde-b316-6fd0e1a24909_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>med-20240805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:272a0a2e-e851-4d4b-9f7d-f044ebddd625,g:0fca923f-655c-4461-900c-20701eed3f36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.medifast1.com/role/Cover" xlink:type="simple" xlink:href="med-20240805.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.medifast1.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0cb02772-5186-4264-8b22-51d692993e4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_DocumentType_0cb02772-5186-4264-8b22-51d692993e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a03065ba-c67d-4911-ab57-2d2036064ee5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_DocumentPeriodEndDate_a03065ba-c67d-4911-ab57-2d2036064ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e07cfa28-9994-40c7-af07-1d40dfc9b2db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityRegistrantName_e07cfa28-9994-40c7-af07-1d40dfc9b2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5df510d6-6468-443e-b3e7-5359e0bd60d4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityAddressAddressLine1_5df510d6-6468-443e-b3e7-5359e0bd60d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f233bbdf-68fb-40d3-b796-b95e8f72fc81" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityAddressCityOrTown_f233bbdf-68fb-40d3-b796-b95e8f72fc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0599e372-7668-4bb3-ae6a-1b7bbd65df59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityAddressStateOrProvince_0599e372-7668-4bb3-ae6a-1b7bbd65df59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb711b3c-8fe6-4099-ae3a-283dd7dc1287" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityAddressPostalZipCode_fb711b3c-8fe6-4099-ae3a-283dd7dc1287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_83200482-449e-4aeb-ab5c-51df86b02030" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_CityAreaCode_83200482-449e-4aeb-ab5c-51df86b02030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_08e18714-a69e-4380-b81c-3c7d1f622482" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_LocalPhoneNumber_08e18714-a69e-4380-b81c-3c7d1f622482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cc9cc759-3121-4470-a0f1-c2268bb9e0b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_Security12bTitle_cc9cc759-3121-4470-a0f1-c2268bb9e0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7e63fc8c-4225-406c-9b3d-111e6ad4f455" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_TradingSymbol_7e63fc8c-4225-406c-9b3d-111e6ad4f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2115db79-75a1-4e71-b83e-b831e76c4d09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_SecurityExchangeName_2115db79-75a1-4e71-b83e-b831e76c4d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_f332429f-7f74-4cb2-9730-3254181aafac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_WrittenCommunications_f332429f-7f74-4cb2-9730-3254181aafac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3e7415a9-5715-498f-bf0e-d31457be3322" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_SolicitingMaterial_3e7415a9-5715-498f-bf0e-d31457be3322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d4bc05f3-95b2-471b-b1ee-64f4275a4786" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_PreCommencementTenderOffer_d4bc05f3-95b2-471b-b1ee-64f4275a4786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_99dd2307-fd02-4df7-af21-5fe32a6e087f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_99dd2307-fd02-4df7-af21-5fe32a6e087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ec6e30f5-3ddd-4259-b078-64113b375a54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityEmergingGrowthCompany_ec6e30f5-3ddd-4259-b078-64113b375a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ec97abe3-fa59-4f4b-8570-f130c5ef09e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityCentralIndexKey_ec97abe3-fa59-4f4b-8570-f130c5ef09e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f322fe94-ca2d-43ac-a12b-e6424f096636" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_AmendmentFlag_f322fe94-ca2d-43ac-a12b-e6424f096636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9d03c580-3492-41f3-8e3e-b6f19a005b92" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityTaxIdentificationNumber_9d03c580-3492-41f3-8e3e-b6f19a005b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cf20e63a-7606-4b4c-ad42-1b81c2d29b85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityFileNumber_cf20e63a-7606-4b4c-ad42-1b81c2d29b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5a06c1dd-6471-4ac8-83e3-b99875385578" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_689eff8d-7a66-446c-a115-f5df76acb6ea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5a06c1dd-6471-4ac8-83e3-b99875385578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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M!-Q%WYU [<:]4*49P<2@.VK\,N.1P-3OXU5XNB[=OK!,LQ0"A6B\Q+KO#UF
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M#_UY"GZ %Q32H&8I!(KN#BBT)%NEZ2!;L:I% 7PV,!JU!3Y:G&IU/L0?/HC
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MPBC(H5$8L'B3N4$:L:(B*0(MMRJNT).B&N47Q\_C?]*M"Z!+6"4P'1U'+;5
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M?,.80J (("@J4%/&4MMKLD63^A+U!DKOL>C7BT;2?GNN7,-K71,8BT0QP(]
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FR0\*?_*GAY(?%/[D3]]+P/\"T78;DKZ")#(     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140355113179616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDIFAST, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 International Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baltimore<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">581-8042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3714405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ "X(%69>*NQS     $P(   L
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MU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ "X(%620>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ "X(%60=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  +@@59!4<)3NX    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    (  N"!5FJQ"(6,P$  "("   /
M  "  440  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  +@@59)!Z;HJT
M  #X 0  &@              @ &E$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  +@@5999!YDAD!  #/ P  $P
M@ &*$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #4$P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="med-20240805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.medifast1.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="med-20240805.htm">med-20240805.htm</File>
    <File>med-20240805.xsd</File>
    <File>med-20240805_lab.xml</File>
    <File>med-20240805_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "med-20240805.htm": {
   "nsprefix": "med",
   "nsuri": "http://www.medifast1.com/20240805",
   "dts": {
    "inline": {
     "local": [
      "med-20240805.htm"
     ]
    },
    "schema": {
     "local": [
      "med-20240805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "med-20240805_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "med-20240805_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.medifast1.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "med-20240805.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "med-20240805.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.medifast1.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-034743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-034743-xbrl.zip
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MR!F8<8"F_":B-R6BI7!: LDU0SX!XD,:H2+GHSJEUINS=[W.TH#E10H%"YD
M#\+2%7)!>353I:^ $E'R:TJ0QFDIY<-1A,JKW@T$8CPO G.2!B ?-=S=&/F0
M:9()]:3,N9E3K5!'JHOW3/&U>.(!/H><":)08BNUM=U]N\CO^Q^WBE>+T$?
MG20HGL TA7P-#K.%]*".HU+=;YNA&:SI6K04S\4@Y06Z"R;-N%*>T\<R:*U6
M7>0.?\Q?_H'<N_LF5_<ACXT!0Z?>]"HC>3SF@1PT;<OZ1TGU:YVD(PKZT!<H
M,?VW!C(#U3J1M!^Q F(_$8">X2=11$<I:Q9_'!>6I;V&H3XZ'E)Q RCT$RF3
M81,Q@!E,<I]&!HWX3=Q$-N3-=\B9ED90 AMD4(R<-YO05%Y^WZB;#6MUDV7:
MZGU9P1-%8\X7=R1+ZAN@!!EP6@(/NDALCC[T)$&2(3-^M-3/\8@&. $W+6(#
MF&*,LB)^E3@T.V0R:E:!%XIXS0<?E)*)DI9'T1TP2D2S&"L$I0%;'_)HVGQU
MS8=@N.=L3*Z2(8U?':7@H,&3"Q[JCBG_'P->PBCJ<:R)K0$<)9Z<>-M!1O]V
MWKWNO":]Z[/K3F]1#>:0WQ=L>YWV;U?=ZVZG1\[.7Y/.[^U_G9W_TB'MB_?O
MN[U>]^)\[TGX0-,!J(U,XB/RVFR;$'%5O,;>H_W')C]KJ=A3Y7]S<?7^GS_:
M5>MX\RFY"*YU?*(G7O"_=>/M\JR[YS(%6[KJG%^3J\[EQ=7U2Q/>92;2C$*6
M(Q/28SX&I\1V22*(73D(#DD2[KT KB$E ]0SP24'J)V)/X!0C)$S7P+ZQ&ZX
MWOY*Q5M)$H8^B/L5&R5"DH/BF5$(?E@J";O%S%2H9A8<-G/[R\G<A12VM_U+
M%=)U=*"W&)8'\,88 H@!?F8$=&I,@7:#Q;,HO=0ZRVXR8$7E2*7;&_N-9Q>Y
M]\3\TSG3%;OA*6:5\AQ:"K:XI=;[SNONF[/>]1'IGK?-/7:GJU7_H#.A8+A(
M+FJ\F)%):$K2$?,Q%0D(CPF7*0%3!P,0AQM*N_3<L7C#-AVGOFTH[CJFX[H/
MAN*[ N5MDB"LRP:*8-\933#<G[>]B(7+[$Q&I3V<<33: ?,3H8HYS2P&)<)>
MVUMQ-P8HHQQ03X+;:R=9+,6TG02+/A&+3)A 2S82R2W"N7.&'LP8+*)C*MC+
MLW=%-08<B1PPL??X_@EQ1AIP'2F!@^+S$KSGA\HR^&X*FYK"&QXQZ-P'4G*U
MKF YRC9<NU)S7YY>MY/AD*>XV+#WN"+KB>;]MZ;!V^OI-9UT\Y*HKY1^46FK
MI9;M&F[-]CRL9KXTK>V:5V;/))WA*$JF+\ =+XJ"G"?F*@U^@47%IW2M9T$@
M6)KF_[P#&':AKC505\LB7:0S5@/1B+P6_'8IDC@BGSAL&_Z\$-?)>!:OU$NM
MGVDD^3!9#E@^>1@51UR(2XB.N%H<W#!X:D#*1,4THG%P'Y=/1>4R@;&B__*1
MCN+R\I95:CD@6>?E.86<+ QW+@4PEX] 23H3YF<2%(5<A&!_+#TD!T R09HW
MS<?VIN!RETV_2HED$1L-DIB16+GV(PSRH@QG.P(A-@4]"-C.2RX/.8B#S147
MK?,,B%I05;O4\FSKOJ(>;EOE?9? _'^)G%R<(VVGU*K4;:-N>9M;P\XU9ULA
MG)?/]M^TWX"39(*<JW*+(/EC;O"@^"%IJVIJ0'KH5<D[FLJ\+/GBC'RN2*S+
M2DP 7:-5%7#GH(^U;[7=Y\R7S;VM+S7,>L7=MK[D66;5J3U)4<BNF)[W<%%H
M*ZP:GU-?RMF-Z4<34A*2)A$/9DO->2N*:KGQ<[.9_'L]=@4( 1C%.[4GK'BY
M!\:@]@9<XS8?O:;@#X@?T33=./7[SN<M^"RH"AQZTV$_B9Z6Q9K@[Q)X6 +G
M^5*"4G16K Z"EQ\/.+RYFPK6)8Z/.IS<8Z\5Q,X-Q3,K2U+2[Y:$I-_P&//J
M9M6L5=2LM@NY;1YGYA/[U';ZRJW-XDRWU,(R',BZ)Q/_XQ$944%N:90Q\G?<
M)&63$>Z)&SQ:.'_<4K\F'=A[@>=.5?O4F;0]M?BY6T'NWB5_37(N#+O8TZ&7
MNN\7=M"G+]9T[ JX?4#V/XGXJ$U_MBUD _78IEJXHU2F/6! $V8G=#02R4AP
M7$3K)Q/29U$RQKP-&S&=(W7C+0EYA$$(3PG'K> !Y#V0[J1\F$62QBS)TFA*
M4DAATW"JOLP_2/J@+K18Z\*&N05YE>L2&D^+MA#2FV2,WV&9C>/:1TH.OG")
M1$%L<@F*[6_ N92QYZG9K!Y>EU!^83$3-"+=&%B9Z9SSS'1,+;W#O4TW/W%K
ML6=6K=6YX+8Y8L,U[<9GY8@/^-H\ %KI;3?4E0\ &L&GS^4A/X![!(/&*">+
M\U60]-$S#G85-;%1\[SCM?[PDU;^_LQ2R</I9_'P2>>:G#] QCR#%HH^5QE8
MD.=4<G\F%[<3XB[" [M&VF^NB.-:)G0\7.#1ZDWQU0<VQ2_M>=^PV[>EV3T(
MD7R007SS'N8VF."BQ]6Z]JVH]1USR##GSK).VQXU;&=.K1>VQLZ4V@//J7I^
MU^OGT.M+P=!;XZ$NM0,>HS%Q$8:X//*8?M>_%?T&)AG^')<>]=^V%QBJ:+^1
MMNN^W_5]!_K>3=.,B:VTOO%=Z]=IO<L,[\#?3.OSOBNT?K]SW6X<( <@O9T2
M7^6]@-9',AXPW#!Z/RF%%!=0!/8AYC?D1B1C.4!&CC!1I2D)6 A#J!WD.O*S
M*D7^>B_LTX='W!D7,7>K':L@T*H<XG*I%H+3-YP5(%8=1"E@Z30P!XC"01B'
MYE>6]S6J0)BS5>*W[KUC5FKU9]Q[KLE_H,SF.MXB%%5I6ZB>&ZK/CGQ)9[4%
M/,7V3DWI.H;MZSRD=V@5;/E%<:6MF?+XG0#69E/0]@>DGS^&>%#;=Z&IW? !
MCXU[KU:Z?[Y4CAR <V<1\_&NECA1DV26,M4+J,^+GG@-!U?U-GVC $I>C15-
M<7!UQPM.%#'0!BV"W?(4OH,I@\8^9EG4]_&$!G;&6T@"*H)4ESN#=9M)W ,Z
MVTPR/RF8GQ>^[(D9JCDZ^9R@XF7,97M]/<)F-US45MYP<2<.VYE-5ZMNM)C[
M:/Y*C%&B+:HI6$1Q0^C2)1EWY"HZK;M/:#]-HDRN_V3=FM7Z&S?T[X&XLZ ;
M9O0%HQ\-&@* )HW&=)HB,Y_VGH^'&?K<QQJZD@V)8UJ.>1=K+OZ^8FD62;6K
M]P*<89YC@$LC;V;>KIV ]\6&Y=!T(SU9SK:>?Y*Q(0)M7<1D\;SP$7G/ A[2
M5!Z1;NR;Y #=<ZF(" XAD8!$-2 4G#ON?0;E9A2F$QK'X/]]M9H&S&-4Q.@^
MU3R"$%(&,4A _LK4P52BIYU?LY@1U](CKX_RUW+KI7#Y#)S<:+8<>*D8=Y4S
M#A*S/D.VA1FP+!T@;S%)&O ^EZ31,&U"I:0^-D!>QV &15U42Y;%$3MH@BA@
M=BF2ZL=CDUP/5+?9_5JK!H-\3V(W?6A>P4X'-(I4K-!GD!=""**61>&A%/*(
M!2HN5.$ S.O@L]C\3O!"X'D3$CV;\>LKTD$<<%5*>(1LH$.M*%H)Y[N5#H]F
MAR/'$(N0-.O_">,@HM@YXK3/(SV$&I1*U$'$XPA($SF1?)[&]0SEL6+[M%C_
M7;LDHI!ON//(*SSOQSA'N..*C?3I;85)'\,Q95.XY,PD,A*"+D C/]WM+^ #
M]/J#')T5EK/AU4[6JID/-P\88#J"^K*99D-PW-/C/?+>#=.RUWKO.Q^M#KY@
MN:C0,651Z4;%A)S$%Q&!5<VJ]W )X/DAU5W3LY[S3/Q\76(WZ=I!\-@9T>I>
M$[?Y?A%=1UEM3@^D^W;E"^3[3UL6V!#L5OO1=J&+&#5\7A+]X/ZZ1:+ZU/]X
M(R#X"XR<OE#]',]1&X9?J!!>>?A *%TYIS&MN\?[BSF977]9!-)YG(T78:I@
M>2#!(12A.CG3T3=@UM-Q]K_S.%O=N'LW)^:YS4F9KMW@]^U8B6UYGVLF>[=4
MUDX %7()N;T^NPSJCD=17U-)B;K.X( -^RP(\GN;5?"/71$26;C?>9OUL+TO
M>VP1$KNSD'A_:B7[L$59'Q4$#*C,!-LTB%Y8^'%WMU@Z?Y^?KH__E7&1IP>;
MK5$>K2JL!QED:S[-L!@^GT;K=#D%=D%#HB_EZC-(]$+,Z!"0<O9Y!\S7,TPQ
M%3B:R4$B@+C@J\M5O)II>Y4G23$<L^X]S5E-KVK6K"=91%TY,WYRV+^[6>3^
M77F/+N79WJ?&]LO<^5:#]I^GS2\5L^^"G'):)K]2!'AIDO<T2F(V7:5)SY,1
M/OTYHUWP='_X^6)8UAYP%LYE0/I2%O%%?=J^;6/8'??Q"MN@2>Y?2;NQE_LD
MOKW<-*6L_UL1]5^1M/X/4$L#!!0    (  N"!5F+SW\T:P(  ' '   0
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M&]%P +WW@C@.1J=UZ/R.A3%WJ%>C'A_XIS%[B)/'Z;B6-7[(IKDR6=% MG4
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M8\IWD!M]'#S35.QU55@K!?A<A.8E_I9;_WV5JRZ]7S42881 7+GJ) $D^M(
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M9_R9LSM,90EQ< 3,A34O0(&^.?3G!/ H\ <!DC##(FZRL5#PI.\ &&W@"">
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M,C R-# X,#4N>'-D4$L! A0#%     @ "X(%62<9ZAG\"0  ?50  !0
M         ( !\Q$  &UE9"TR,#(T,#@P-5]L86(N>&UL4$L! A0#%     @
M"X(%61>6/#NF!@  WS   !0              ( !(1P  &UE9"TR,#(T,#@P
M-5]P<F4N>&UL4$L! A0#%     @ "X(%66?SE6E9*0  '2H" !X
M     ( !^2(  &UE9&5A<FYI;F=S<F5L96%S93 X,#4R,#(T+FAT;5!+!08
1    !0 % $P!  ".3      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>med-20240805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="med-20240805.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910329</identifier>
        </entity>
        <period>
            <startDate>2024-08-05</startDate>
            <endDate>2024-08-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000910329</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">MEDIFAST, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-31573</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">13-3714405</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 International Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Baltimore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">21202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">581-8042</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">MED</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NYSE</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
